Similarly, FXR agonists like OCA are beneficial in reducing liver fibrosis in MASH, but their broader effects, including raising LDL cholesterol and causing pruritus, can complicate treatment [120]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.